Home Cart Sign in  
Chemical Structure| 4707-32-8 Chemical Structure| 4707-32-8

Structure of β-Lapachone
CAS No.: 4707-32-8

Chemical Structure| 4707-32-8

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

β-Lapachone is a naturally occurring quinone obtained from the bark of the lapacho tree (Tabebuia avellanedae) with cancer chemopreventive properties and a potent inhibitor of IDO1 (IC50=0.44 μM).

Synonyms: ARQ-501; NSC-26326; SL 11001

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Product Citations

Peng, Xiaohua ; Ali, Taufeeque ; Ponnamperumage, Thilini Nimasha Fernando ; Peterson, Alexis Kimberly ; Li, Daniel ; Gao, Hanlun , et al.

Abstract: Developing targeted cancer therapy with minimal side effects remains a significant challenge. Oxidative stress-based cancer therapies have gained traction in recent years. However, challenges such as limited tumor selectivity and therapeutic durability often hinder their clinical application. Here, we report a novel strategy of combining ROS-responsive prodrugs with prooxidants to achieve potent, durable, and selective tumor killing effects. This approach leverages pro-oxidants (i.e. ascorbate) to amplify oxidative stress within tumors, sensitizing cancer cells to ROS-responsive prodrugs. Both in vitro and in vivo studies confirm the anticancer synergism and selectivity of this combination therapy, which achieved complete tumor regression without recurrence, significantly outperforming single-agent treatments. This combination therapy is effective against hard-to-treat cancers like triple-negative breast cancer and glioblastoma. Our findings highlight the potential of targeting tumor redox mechanisms through a combination of ROS-responsive prodrugs and pro-oxidants, offering a promising avenue for repurposing these agents in cancer therapy.

Keywords: combination therapy ; synergistic anticancer effects ; ROS-responsive prodrugs ; triple negative breast cancer ; ROS-generating agents ; vitamin C ; complete tumor regression

Purchased from AmBeed:

Alternative Products

Product Details of β-Lapachone

CAS No. :4707-32-8
Formula : C15H14O3
M.W : 242.27
SMILES Code : O=C1C(CCC(C)(C)O2)=C2C3=CC=CC=C3C1=O
Synonyms :
ARQ-501; NSC-26326; SL 11001
MDL No. :MFCD01712233
InChI Key :QZPQTZZNNJUOLS-UHFFFAOYSA-N
Pubchem ID :3885

Safety of β-Lapachone

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Related Pathways of β-Lapachone

DNA

Isoform Comparison

Biological Activity

Target
  • Topo I

In Vitro:

Cell Line
Concentration Treated Time Description References
LNCaP cells 1–5 μM 4 h Induced apoptosis, observed G0/G1 phase block and increased apoptotic cell populations PMC4807624
PC-3 cells 1–5 μM 4 h Induced apoptosis, observed G0/G1 phase block and increased apoptotic cell populations PMC4807624
DU-145 cells 1–5 μM 4 h Induced apoptosis, observed G0/G1 phase block and increased apoptotic cell populations PMC4807624
BT549 0.5 μM 48 h Β-lapachone significantly enhanced the sensitivity of BT549 cells to phenformin, reducing tumor cell proliferation. PMC8175605
BT474 1.0 μM 48 h Β-lapachone significantly enhanced the sensitivity of BT474 cells to phenformin, reducing tumor cell proliferation. PMC8175605
MDA-MB-231 0.5 μM 48 h Β-lapachone significantly enhanced the sensitivity of MDA-MB-231 cells to phenformin, reducing tumor cell proliferation. PMC8175605
HL-60 cells ≥0.5 μM 4 h Induced apoptosis, observed 180-200 bp oligonucleosome DNA laddering and apoptotic cells via flow cytometry PMC4807624
MDA-MB-231 cells 10 μM 2 h To evaluate the effect of β-Lapachone on PP-InsP levels in NQO1-deficient cells, the results showed that β-Lapachone did not affect 5-PP-InsP5 levels but significantly reduced ATP levels. PMC10450438
HCT116 cells 2.5 μM, 5 μM, or 10 μM 2 h To evaluate the effect of β-Lapachone on PP-InsP levels, the results showed that β-Lapachone dose-dependently decreased PP-InsP levels, while InsP6 levels remained stable. PMC10450438
MDA-MB-231 cells 10 μM 2 h In MDA-MB-231 cells, which lack NQO1, β-lapachone did not reduce PP-InsP levels, but ATP levels dropped significantly. PMC10450438
MDA-MB-231 breast cancer cells 6 μM 2 h To evaluate the cytotoxicity of β-Lapachone micelles on NQO1-overexpressing cells, results showed more than 50% cell death in NQO1+ cells at a 6 μM dose. PMC2064869
DU-145 prostate cancer cells 6 μM 2 h To evaluate the cytotoxicity of β-Lapachone micelles on NQO1-overexpressing cells, results showed more than 50% cell death in NQO1+ cells at a 6 μM dose. PMC2064869
H596 non-small cell lung cancer cells 5 μM, 10 μM 2 h To evaluate the cytotoxicity of β-Lapachone micelles on NQO1-overexpressing cells, results showed 26% and 85% cell death in NQO1+ cells at 5 μM and 10 μM doses, respectively. PMC2064869
ShNQO1 A549 cells 10 μM 4 h In shNQO1 A549 cells, β-lap had a weaker inhibitory effect on NF-κB, indicating that NQO1 plays a crucial role in β-lap-mediated suppression of NF-κB activation. PMC2877251
A549 human lung cancer cells 10 μM 4 h Suppressed radiation-induced NF-κB activation, almost completely abrogated NF-κB DNA binding activity, and inhibited the transcription of NF-κB target genes. PMC2877251
IMR-90 fibroblasts >40 µM IMR-90 fibroblasts were resistant to the cytotoxic effects of β-Lapachone. PMC1913860
A549 NSCLC cells 2.5 µM 2 h Β-Lapachone killed A549 cells in an NQO1-dependent manner, inducing ROS formation, DNA damage, PARP-1 hyperactivation, NAD+/ATP depletion, and apoptosis. PMC1913860
H596 NSCLC cells 4 µM 2 h Β-Lapachone killed NSCLC cells in an NQO1-dependent manner, inducing ROS formation, DNA damage, PARP-1 hyperactivation, NAD+/ATP depletion, and apoptosis. PMC1913860
CHEF/18A cells 4 μM 5 h Β-Lapachone inhibited potentially lethal DNA damage repair (PLDR) processes, thereby reducing x-ray-induced cell transformation. At equivalent survival levels, β-Lapachone treatment resulted in an 8-fold decrease in transformation frequency. PMC297536

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Mice MDA-MB-231 mammary tumor model Intraperitoneal injection 25 mg/kg Β-lapachone every 2 days, phenformin daily, continuous treatment Combined β-lapachone and phenformin treatment significantly inhibited MDA-MB-231 mammary tumor growth and increased oxidative damage in mammary tumors. PMC8175605

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT03575078 Lymphoma Phase 1 Not yet recruiting August 23, 2023 -

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

4.13mL

0.83mL

0.41mL

20.64mL

4.13mL

2.06mL

41.28mL

8.26mL

4.13mL

 

Historical Records

Categories